Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers

Covid19 Clinical Trial

Official title:

A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05047692
• Other study ID #: AdCLD-CoV19-1-001
• Status: Completed
• Phase: Phase 1
• Start date: September 9, 2021
• Est. completion date: June 21, 2023

Study information

• Verified date: July 2023
• Source: Cellid Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 clinical trial to assess the safety and immunogenicity of AdCLD-CoV19-1 in healthy adults.

Description:

This is a dose-escalation, multi-center, open-label, Phase 1 clinical trial. We assess the safety of AdCLD-CoV19-1 and immune responses against SARS-CoV-2. DSMB will evaluate safety when events occurred during the whole study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 21, 2023
• Est. primary completion date: December 2, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 64 Years

Eligibility

Inclusion Criteria:

• Able and willing to agree informed consent and aged 19 to 64 years.

• The BMI index is 18.5 kg/m2 to 30.0 kg/m2.

• Able and willing to medically effective contraception during the whole study period.

• Agreement to refrain from blood donation during the whole study period.

Exclusion Criteria:

• Anyone deemed infected by COVID-19.

• Determined to be a close-contact of SARS-CoV-2 confirmed case or classified to symptomatic patient of COVID-19 prior to vaccination.

• Clinically significant abnormal ranges of laboratory measurement, ECG, Chest X-ray at screening visit.

• Positive in HIV, HBV, HCV test at screening visit.

• Acute fever(= 38?) or suspected infectious disease, symptoms of infectious disease(cough, difficulty breathing, chills, muscle aches, headache, sore throat, loss of smell, or loss of taste, etc.) within 3 days prior to vaccination.

• Chronic respiratory disease: Asthma, chronic obstructive pulmonary disease, active tuberculosis, latent tuberculosis under treatment.

• Clinically significant active or any history of disease: Hepatobiliary system, kidney, central or peripheral nervous system (epilepsy, seizure, etc.), endocrine system (uncontrolled diabetes, hyperlipidemia, etc.), cardiovascular system (congestive heart failure, coronary artery disease, myocardial infarction, control Hypertension, etc.), blood tumor, urinary system, mental, musculoskeletal system, immune system (rheumatoid arthritis, systemic lupus erythematosus).

• Immunosuppressive disease including immunodeficiency disease.

• Scheduled to undergo any surgery during the whole study period.

• Healthcare worker who provide medical care to SARS-CoV-2 cases or occupationally in high risk for SARS-CoV-2 exposure during the whole study period.

• Prisoners or subjects who are compulsorily detained. (involuntary incarceration)

• History of SARS or MERS.

• Allergic reaction or hypersensitivity to any ingredient of AdCLD-CoV19-1.

• Having hemophilia at risk of causing serious bleeding when injected intramuscularly or receiving anticoagulants.

• Any history of malignant disease within the past 5 years. History of hypersensitivity to inoculate vaccine such as Guillain-Barre syndrome.

• History of serious adverse reaction or allergic reaction to inoculate vaccine.

• Urticaria past 5 years prior to vaccination.

• History of hereditary angioneurotic edema or acquired angioneurotic edema.

• History of solid organ or bone marrow transplantation.

• Suspected or a history of drug or alcohol abuse past 12 month before vaccination.

• Receipt of vaccine of SARS-CoV, MERS-CoV, SARS-CoV-2.

• Receipt of adenovirus vector based vaccine.

• Chronic use of immunosuppressant or immune modifying drug within 6 months prior to vaccination. (use of inhaled, topical, nasal, and ophthalmic corticosteroids are allowed)

• Having relied on antipsychotic drugs and narcotic analgesics within 6 months before vaccination or difficult to comply with the clinical trial procedure at the judgment of the investigator.

• Administered to other investigational product or medical device within 6 months before vaccination.

• Other vaccination history within 30 days prior to vaccination or being scheduled within 30 days after vaccination.

• Receipt of immunoglobulin or any blood product within 3 month prior to vaccination.

• Pregnant(including positive hCG test at screening visit) or breastfeeding female.

• Those who are directly related to the investigator.

• Other condition deemed ineligible for the study at the discretion of investigator.

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Biological:
• AdCLD-CoV19-1
Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein

Locations

Country	Name	City	State
Korea, Republic of	Korea University Ansan Hospital	Ansan	Province
Korea, Republic of	Korea University Guro Hospital	Seoul	State
Korea, Republic of	The Catholic University of Korea, ST. Vincent's Hospital	Suwon	Province

Sponsors (1)

Lead Sponsor	Collaborator
Cellid Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	GMT of S protein receptor binding domain(RBD) specific antibody		2, 4, 26, 52 weeks post-vaccination
Primary	Incidence of solicited adverse events(AEs)		Through 7 days post-vaccination
Primary	Incidence of unsolicited AEs		Through 28 days post-vaccination
Secondary	Incidence of serious adverse events(SAEs)		Through 12 months post-vaccination
Secondary	Incidence of adverse events of special interest(AESIs)		Through 12 months post-vaccination
Secondary	Seroconversion rate(SCR) of neutralization antibody against wild type SARS-CoV-2		4 weeks post-vaccination
Secondary	Geometric mean titer(GMT) of neutralization antibody against wild type SARS-CoV-2		4 weeks post-vaccination
Secondary	GMT of S protein specific antibody		2, 4, 26, 52 weeks post-vaccination
Secondary	S protein specific T cell response		2, 4, 26, 52 weeks post-vaccination